{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=52", "query": { "condition": "Neuroendocrine Tumours", "page": 52 }, "page_size": 10 }, "pagination": { "page": 52, "page_size": 10, "total_count": 2737, "total_pages": 274, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=53&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=51&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T03:13:53.028Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05954546", "title": "A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Enco+bini", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2023-07-21", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05954546" }, { "nct_id": "NCT02489903", "title": "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma", "Carcinoma, Non-Small-Cell Lung", "Neuroendocrine Tumors", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2015-06", "completion_date": "2021-12-06", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 10, "location_summary": "Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489903" }, { "nct_id": "NCT03220217", "title": "To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro-Enteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Satoreotide trizoxetan 5-20μg", "type": "DRUG" }, { "name": "Satoreotide trizoxetan 30-45μg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-09-26", "completion_date": "2019-08-05", "has_results": true, "last_update_posted_date": "2021-01-14", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220217" }, { "nct_id": "NCT00912418", "title": "Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "autologous tumor cells plus GM-CSF-in Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 14, "start_date": "2000-05-01", "completion_date": "2002-10-09", "has_results": false, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00912418" }, { "nct_id": "NCT04588246", "title": "Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Breast Neoplasm", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Recurrent Brain Neoplasm", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Memantine", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Whole-Brain Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-08-05", "completion_date": "2024-08-06", "has_results": true, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 79, "location_summary": "Tucson, Arizona • Corona, California • Duarte, California + 63 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04588246" }, { "nct_id": "NCT00996827", "title": "Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "New Mexico Cancer Research Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 100, "start_date": "2009-01", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-06-18", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 2, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00996827" }, { "nct_id": "NCT03088176", "title": "Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "BRAF Gene Mutation" ], "interventions": [ { "name": "Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil", "type": "DRUG" }, { "name": "Talimogene Laherparep 100 Mil Pfu/Ml 1Ml", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2017-06-25", "completion_date": "2021-06-30", "has_results": false, "last_update_posted_date": "2020-10-12", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 1, "location_summary": "Germantown, Tennessee", "locations": [ { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03088176" }, { "nct_id": "NCT02587650", "title": "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ALK Fusion Protein Expression", "BRAF wt Allele", "Invasive Skin Melanoma", "MET Fusion Gene Positive", "NRAS wt Allele", "NTRK1 Fusion Positive", "NTRK2 Fusion Positive", "NTRK3 Fusion Positive", "RET Fusion Positive", "ROS1 Fusion Positive", "Stage III Cutaneous Melanoma", "Stage IIIA Cutaneous Melanoma", "Stage IIIB Cutaneous Melanoma", "Stage IIIC Cutaneous Melanoma", "Stage IV Cutaneous Melanoma" ], "interventions": [ { "name": "Capmatinib", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-03-26", "completion_date": "2018-07-12", "has_results": true, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02587650" }, { "nct_id": "NCT01807182", "title": "Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Metastatic Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Therapeutic Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-08-20", "completion_date": "2021-08-26", "has_results": true, "last_update_posted_date": "2022-11-10", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807182" }, { "nct_id": "NCT02716948", "title": "SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Spine", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2016-06-23", "completion_date": "2021-08-27", "has_results": false, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-10-20T03:13:53.028Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02716948" } ] }